-
Posted by
Two Blokes Jul 10 -
Filed in
Stock
-
3 views
Eli Lilly reported impressive data from bimagrumab and eloralintide programs, reinforcing its leadership in obesity therapeutics. Results from competitors were either as expected or underwhelming. Favorable commercial trends for tirzepatide and a robust pipeline—including orforglipron and retatrutide—support Lilly's continued market dominance for the next 5-7 years.
